Clinical characteristics of long-term survivors (ie, patients that survived at least 5 years or more after the ILR)
| Patient | Age* (years) | FIGO grade | LVSI | Adjuvant therapy | LR in an area that was not previously irradiated† | Isolated lymphatic recurrence site | Time of recurrence following surgery (years) | Treatment of ILR | Years from ILR to last follow-up | Status at last follow-up |
| 1 | 39 | 3 | No | EBRT+VBT | Yes | PA | 2.5 | Surgery+EBRT | 24.0 | Alive |
| 2 | 52 | 3 | Yes | CHT | Yes | Multiple (PA and supraclavicular) | 0.4 | Surgery+CHT | 11.4 | Alive |
| 3 | 53 | 1 | No | CHT | Yes | PA | 2.5 | Surgery+EBRT | 13.0 | Alive |
| 4‡ | 59 | 2 | No | VBT | Yes | PA | 2.4 | EBRT | 6.8 | Alive |
| 5 | 53 | 3 | Yes | EBRT+VBT | Yes | PA | 2.0 | Surgery+CHT | 13.8 | Alive |
| 6 | 50 | 2 | No | EBRT+VBT | Yes | PA | 0.6 | Surgery, EBRT, and CHT | 11.3 | Alive |
| 7 | 70 | 2 | No | VBT | Yes | PA | 0.9 | Surgery+CHT | 6.6 | Alive |
| 8 | 57 | 1 | No | None | Yes | PA | 0.4 | EBRT | 7.0 | Alive |
| 9‡ | 58 | 1 | Yes | EBRT | No | Multiple (P and PA) | 0.5 | HT | 7.2 | Dead |
| 10‡ | 87 | 2 | n/a | EBRT | No | P | 0.4 | HT | 6.5 | Dead |
| 11 | 84 | 1 | No | None | Yes | Distant | 2.1 | Surgery+EBRT | 5.2 | Dead |
| 12‡ | 50 | 1 | No | EBRT | Yes | Distant | 0.8 | EBRT | 19.0 | Dead |
| 13‡ | 62 | 3 | Yes | EBRT | Yes | Distant | 0.3 | HT | 8.6 | Dead |
| 14 | 63 | 1 | No | None | Yes | Multiple (N/A) | 6.7 | Surgery+HT | 14.9 | Dead |
| 15 | 68 | 1 | No | VBT | Yes | Multiple (PA and mediastinal) | 0.7 | CHT and EBRT | 5.9 | Dead |
All patients had endometrioid histology, except for patient number 13, whose tumor was non-endometrioid.
*At primary surgery.
†In the case of multiple sites of ILR, such as pelvic and para-aortic recurrence, all the areas need to be not irradiated to consider the ILR as a recurrence in a non-irradiated area.
‡No pathologic confirmation of the recurrence. Diagnosis of recurrence was based on clinical and radiologic suspicion and further consolidated based on response to treatment for the recurrence.
CHT, chemotherapy; EBRT, external beam radiation therapy; FIGO, International Federation of Gynecology and Obstetrics; HT, hormonal therapy; ILR, isolated lymphatic recurrence; LR, lymphatic recurrence; LVSI, lymphovascular space invasion; N/A, not available; P, pelvic; PA, para-aortic; VBT, vaginal brachytherapy.